Spondyloarthritis & psoriatic arthritis
Factors associated with treatment intensification in patients with axial spondyloarthritis and high disease activity in clinical practice
Authors' conclusion
In practice, treatment is intensified in a minority of axSpA patients with HDA. Physician-centred factors are associated with the decision to change treatment, independently of disease activity or patient perspective.
Study context
- Population
- Patients with axial SpA (axSpA) and high disease activity (Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥2.1) from the Dutch SpA-Net registry
- Participants
- 121 patients
- Outcome
- Treatment intensification (higher dose or shorter interval of the same drug, switch due to inefficacy, or addition of a new drug; anti-inflammatory drugs only)
Methodological detailsDutch SpA-Net registry, multivariable logistic regression, patient-centred and physician-centred models, sensitivity analyses
- Dutch SpA-Net registry
- Multivariable logistic regression
- Patient-centred and physician-centred models
- Sensitivity analyses
Main finding
As reported in the abstract
Treatment intensification (TI) conducted (mainly switch or addition of a drug)
41/121, 33.9%
Higher ASDAS associated with TI, patient-centred model: OR
1.94 (1.00-3.74) (95% CI)
Physician global assessment (PhGA) associated with TI, physician-centred model: OR
1.71
1.24–2.34
PASS-physician associated with TI, physician-centred model: OR
94.95
Observational data: associations, not effects.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →